Rubric Capital Amends Mereo BioPharma Stake Filing

TL;DR

Rubric Capital just updated their Mereo BioPharma filing - watch this space.

AI Summary

Rubric Capital Management LP, on June 17, 2024, filed an amendment to its Schedule 13D, indicating a change in its beneficial ownership of Mereo BioPharma Group plc ordinary shares. The filing does not specify the exact number of shares or the percentage of ownership, but it signifies an ongoing relationship and potential strategic interest from Rubric Capital in Mereo BioPharma.

Why It Matters

This amendment signals potential shifts in significant shareholder influence or strategy concerning Mereo BioPharma Group plc, which could impact its stock performance and corporate direction.

Risk Assessment

Risk Level: medium — Amendments to Schedule 13D filings often indicate changes in a significant shareholder's stake or intentions, which can lead to increased volatility.

Key Players & Entities

• Rubric Capital Management LP (company) — Filing entity
• Mereo BioPharma Group plc (company) — Subject company
• Brian Kleinhaus (person) — Person authorized to receive notices
• June 17, 2024 (date) — Filing date

FAQ

Filing Documents

• tm2417424d1_sc13da.htm (SC 13D/A) — 53KB
• 0001104659-24-072315.txt ( ) — 55KB

of the Schedule 13D is hereby amended by adding the following

Item 4 of the Schedule 13D is hereby amended by adding the following. On June 14, 2024, the Issuer filed a Form 8-K dated June 14, 2024 (the “Form 8-K”), and a Form 424B5 dated June 14, 2024, with the Securities and Exchange Commission in connection with an underwritten offering of 12,531,300 ADSs (such Form 424B5, “Form 424B5,” and such offering, the “Offering”) by the Issuer. The Reporting Persons have purchased 1,754,350 ADSs in the Offering. The Reporting Persons are subject to a lock-up agreement with respect to such ADSs, a form of which is attached as an exhibit to the Underwriting Agreement dated June 14, 2024 between the Issuer and the underwriters to the Offering (the “Underwriting Agreement,” a form of which is attached as Exhibit 1.1 to the Form 8-K). Item 5. INTERESTS IN SECURITIES OF THE ISSUER a) See rows (11) and (13) of the cover pages to this Schedule 13D for the aggregate number of Ordinary Shares and percentages of the Ordinary Shares beneficially owned by each of the Reporting Persons. The percentages used in this Schedule 13D are calculated based upon 764,005,934 Ordinary Shares reported to be outstanding as of June 17, 2024 in Form 424B5. c) Schedule A annexed hereto lists all transactions in the securities of the Issuer by the Reporting Persons since the filing of Amendment No. 13. All such transactions were effected in the open market unless otherwise noted herein. CUSIP No. 589492107 SCHEDULE 13D Page 5 of 6 Pages

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct. Date: June 17, 2024 RUBRIC CAPITAL MANAGEMENT LP By: /s/ Michael Nachmani Name: Michael Nachmani Title: Chief Operating Officer /s/ David Rosen DAVID ROSEN CUSIP No. 589492107 SCHEDULE 13D Page 6 of 6 Pages SCHEDULE A Transactions in the Securities of the Issuer Since the Filing of Amendment No. 13 Nature of Transaction Securities Purchased Price per Security ($) Date of Purchase/Sale Purchase of ADS 1,754,350 3.99 06/17/2024

View Full Filing

View this SC 13D/A filing on SEC EDGAR